158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-002408-13-NL (EUCTR) | 07/02/2017 | 25/07/2016 | Bumetanide to treat behavioral problems in TSC | Bumetanide to Ameliorate Tuberous Sclerosis Complex Hyperexcitable Behaviors - BATSCH | Tuberous Sclerosis Complex MedDRA version: 20.0;Level: PT;Classification code 10045138;Term: Tuberous sclerosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Trade Name: bumetanide Product Name: bumetanide Product Code: bumetanide | UMC Utrecht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Netherlands |